On June 7, 2021 C&Cure, a startup that possesses a bacterial platform for cancer treatment and radiopharmaceutical technology for diagnosis, reported the company developed a precision immunotherapy platform (SAM-04) using the characteristics of bacteria that cluster in tumors (Press release, CNCure, JUN 7, 2021, View Source [SID1234649032]). This technology activates surrounding immune cells and removes cancerous tissues when bacteria infiltrate the tumor.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
C&Cure has developed a radiopharmaceutical that can diagnose malignant melanoma and infections by utilizing radiolabeling technology as well as a bacterial platform for cancer treatment. A radiopharmaceutical for malignant melanoma diagnosis ([ 18 F] DMPY2) with a benzamide-based chemical skeleton structure detected malignant melanoma with ultrahigh sensitivity in small animal tumor and metastasis models. When comparing the degree of distribution in vivo with [ 18 F] FDG, which is currently the most widely used in clinical practice , [ 18 F] DMPY2 was found to have superior selectivity for detecting malignant melanoma and a significantly higher signal ratio in normal tissue compared to tumor tissue.
Also, radiopharmaceuticals for diagnosing fungal and gram-negative bacterial infections ( [ 18 F] FDS) are radiopharmaceuticals developed based on the fact that sorbitol is used as a nutrient for microorganisms. Positron emission tomography (PET) images can be used to rapidly and highly visualize fungal and gram-negative bacterial infections. Compared to existing diagnostic methods, it can quickly and non-invasively confirm infection, and it can even diagnose the location of infection with high sensitivity and specificity.
C&Cure has secured technology and resources for each platform, and has global competitiveness, and the total investment attracted to date has reached 9 billion won.